TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Triple Negative ◽

Phase Ii Trial ◽

Death Receptor ◽

Death Receptor 5

TBCRC 019: An open-label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 (DR5) monoclonal antibody tigatuzumab in patients with metastatic, triple-negative (ER, PR, and HER2-negative) breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps128 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS128-TPS128 ◽

Cited By ~ 1

Author(s):

A. Forero-Torres ◽

N. U. Lin ◽

M. C. Liu ◽

H. S. Rugo ◽

S. Puhalla ◽

...

Keyword(s):

Breast Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Death Receptor ◽

Death Receptor 5 ◽

Open Label ◽

Abstract P1-04-01: Significance of circulating tumor cells in metastatic triple negative breast cancer: Results of an open label, randomized, phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 tigatuzumab (TBCRC 019)

10.1158/0008-5472.sabcs13-p1-04-01 ◽

2013 ◽

Author(s):

C Paoletti ◽

Y Li ◽

MC Muñiz ◽

KM Kidwell ◽

K Aung ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Triple Negative ◽

Phase Ii Trial ◽

Death Receptor ◽

Death Receptor 5 ◽

Open Label ◽

Faculty Opinions recommendation of Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717985140.793472566 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Neoadjuvant Treatment ◽

Multicentre Phase

CSC ‐3436 sensitizes triple negative breast cancer cells to TRAIL ‐induced apoptosis through ROS ‐mediated p38/ CHOP /death receptor 5 signaling pathways

Environmental Toxicology ◽

10.1002/tox.23372 ◽

2021 ◽

Author(s):

Chun‐Chen Huang ◽

Yi‐Ching Cheng ◽

Ying‐Chao Lin ◽

Chun‐Hung Chou ◽

Chi‐Tang Ho ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Cells ◽

Signaling Pathways ◽

Breast Cancer Cells ◽

Triple Negative ◽

Death Receptor ◽

Death Receptor 5 ◽

Induced Apoptosis

OT3-01-14: N0937: Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.

10.1158/0008-5472.sabcs11-ot3-01-14 ◽

2011 ◽

Author(s):

A Moreno-Aspitia ◽

KM Rowland ◽

H Liu ◽

DW Hillman ◽

PJ Stella ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial

Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

10.1158/1538-7445.sabcs15-s6-07 ◽

2016 ◽

Cited By ~ 6

Author(s):

O Gluz ◽

U Nitz ◽

C Liedtke ◽

M Christgen ◽

K Sotlar ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)

Breast Cancer Research and Treatment ◽

10.1007/s10549-019-05259-z ◽

2019 ◽

Vol 176 (3) ◽

pp. 607-615

Author(s):

Christel Fontaine ◽

Vincent Renard ◽

Heidi Van den Bulk ◽

Peter Vuylsteke ◽

Philip Glorieux ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Medical Oncology ◽

Phase Ii Trial ◽

Task Force ◽

Belgian Society ◽

Prospective Phase

Randomized phase II trial to evaluate the safety and efficacy of neoadjuvant cisplatin in combination with taxanes-anthracyclines vs taxanes-anthracyclines alone in locally advanced triple negative breast cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e12024 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e12024-e12024 ◽

Cited By ~ 7

Author(s):

Maria Cristina Aguilar Martinez ◽

Claudia Arce-Salinas ◽

Alberto Alvarado-Miranda ◽

Fernando Lara-Medina ◽

Diana flores-Diaz ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Locally Advanced ◽

Safety And Efficacy ◽

Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP)

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3646 ◽

2020 ◽

pp. clincanres.3646.2020

Author(s):

Priyanka Sharma ◽

Bruce F Kimler ◽

Anne P O'Dea ◽

Lauren Nye ◽

Yen Y Wang ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Stage I ◽